July 10th 2025
Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.
Comorbidities Among HIV Patients with Commercial Insurance, Medicare, and Medicaid
January 1st 2018Due to living longer and other factors, comorbidities are common in HIV-infected patients on antiretroviral therapy (ART) no matter what type of insurance they have—although some conditions are more prevalent with certain payers.
Read More
PrEP Uptake of 25% Enough to Prevent 30% of HIV Infections in MSM
December 14th 2017A new study from investigators at Drexel University revealed that if 25% of high-risk men who have sex with men appropriately used the pre-exposure prophylaxis (PrEP), 3 out of every 10 HIV infections in this population could be prevented.
Read More
Study Finds No Benefit for HIV Therapeutic Vaccine Following ART Interruption
December 11th 2017However, findings from the study may provide a roadmap for future analyses of immune-based interventions seeking to relieve HIV patients of the lifelong burden of daily medication intake and enhance viral suppression.
Read More